Health
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial – The Lancet
In FAVOR III China, among patients undergoing PCI, a QFR-guided strategy of lesionselection improved 1-year clinical outcomes…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The…
Continue Reading
